Open AccessPartial response to Chinese patent medicine Kangliu pill for adult glioblastoma: A case report and review of the literature
Author(s) -
Guoqiang Sun,
Wei Zhuang,
Lin Q,
LeiMing Wang,
Yuhang Zhen,
Shengyan Xi,
Xiaolan Lin
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i12.2845
Subject(s) - medicine , pill , traditional medicine , glioblastoma , traditional chinese medicine , chinese patent medicine , alternative medicine , pharmacology , pathology , cancer research
Glioblastoma is the most common type of brain tumor and is invariably fatal, with a mean survival time of 8-15 mo for recently diagnosed tumors, and a 5-year survival rate of only 7.2%. The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide. However, the prognosis remains poor and long-term survival is rare. This report aimed to demonstrate a new therapeutic strategy for the treatment of glioblastoma.